Previous 10 | Next 10 |
2024-04-06 01:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ). The investigation concerns whether Zymeworks and/or certain of its officers...
2024-04-01 12:43:41 ET More on Zymeworks Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks Non-GAAP EPS of -$0.16 ...
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appoin...
2024-03-27 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-16 22:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-08 10:18:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the stock markets, fortunes rise and fall on the tide of hype and advancements, with the tech sector impacted the most. As the world is in the middle of a decade, the stage is set for the li...
2024-03-07 17:04:26 ET More on Zymeworks Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks Non-GAAP EPS of -$0.16 ...
2024-03-06 23:17:10 ET Zymeworks Inc. (ZYME) Q4 2023 Earnings Conference Call March 6, 2024, 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Dr. Chris Astle - Senior Vice President and CFO Paul Moore - Chief Scientific Officer K...
2024-03-06 17:42:05 ET More on Zymeworks Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks Non-GAAP EPS of -$0.16 beats by $0.28, revenue of $16.92M misses by $0.74M Read the full article on Seeking Alpha For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License A...